Geode Capital Management
GALT icon

Geode Capital Management’s Galectin Therapeutics GALT Stock Holding History

Geode Capital Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.71M Buy
612,786
+14,712
+2% +$44.8K ﹤0.01% 3185
2025
Q4 		$2.49M Sell
598,074
-34,993
-6% -$184K ﹤0.01% 3083
2025
Q3 		$2.68M Sell
633,067
-33,124
-5% -$125K ﹤0.01% 3083
2025
Q2 		$1.41M Sell
666,191
-186,515
-22% -$279K ﹤0.01% 3234
2025
Q1 		$1.04M Sell
852,706
-17,883
-2% -$25.1K ﹤0.01% 3299
2024
Q4 		$1.12M Buy
870,589
+8,047
+0.9% +$19.3K ﹤0.01% 3330
2024
Q3 		$2.37M Buy
862,542
+20,817
+2% +$51.1K ﹤0.01% 3067
2024
Q2 		$1.9M Buy
841,725
+274,564
+48% +$834K ﹤0.01% 3139
2024
Q1 		$1.36M Buy
567,161
+52,745
+10% +$99.8K ﹤0.01% 3249
2023
Q4 		$854K Buy
514,416
+3,985
+0.8% +$7.73K ﹤0.01% 3410
2023
Q3 		$980K Sell
510,431
-11,855
-2% -$19.5K ﹤0.01% 3328
2023
Q2 		$752K Buy
522,286
+608
+0.1% +$1.03K ﹤0.01% 3464
2023
Q1 		$1.1M Buy
521,678
+7,863
+2% +$12.7K ﹤0.01% 3306
2022
Q4 		$580K Sell
513,815
-87
-0% -$116 ﹤0.01% 3594
2022
Q3 		$837K Buy
513,902
+2,763
+0.5% +$5.16K ﹤0.01% 3485
2022
Q2 		$669K Sell
511,139
-47,101
-8% -$67.7K ﹤0.01% 3603
2022
Q1 		$898K Sell
558,240
-1,488
-0.3% -$2.88K ﹤0.01% 3667
2021
Q4 		$1.16M Buy
559,728
+18,862
+3% +$53.9K ﹤0.01% 3645
2021
Q3 		$2.1M Buy
540,866
+131,853
+32% +$447K ﹤0.01% 3323
2021
Q2 		$1.31M Sell
409,013
-236,854
-37% -$843K ﹤0.01% 3467
2021
Q1 		$1.4M Buy
645,867
+3,763
+0.6% +$8.43K ﹤0.01% 3420
2020
Q4 		$1.44M Buy
642,104
+47,483
+8% +$125K ﹤0.01% 3242
2020
Q3 		$1.59M Buy
594,621
+921
+0.2% +$2.58K ﹤0.01% 3000
2020
Q2 		$1.82M Buy
593,700
+32,332
+6% +$81.3K ﹤0.01% 2900
2020
Q1 		$1.1M Buy
561,368
+16,795
+3% +$40.9K ﹤0.01% 2984
2019
Q4 		$1.56M Buy
544,573
+74,017
+16% +$257K ﹤0.01% 3111
2019
Q3 		$1.73M Buy
470,556
+1,493
+0.3% +$5.4K ﹤0.01% 3018
2019
Q2 		$1.95M Buy
469,063
+189,315
+68% +$820K ﹤0.01% 2970
2019
Q1 		$1.43M Buy
279,748
+52,573
+23% +$252K ﹤0.01% 3019
2018
Q4 		$779K Buy
227,175
+15,410
+7% +$73.6K ﹤0.01% 3210
2018
Q3 		$1.27M Buy
211,765
+9,202
+5% +$50.6K ﹤0.01% 3115
2018
Q2 		$1.29M Buy
202,563
+7,152
+4% +$34.8K ﹤0.01% 3079
2018
Q1 		$926K Hold
195,411
– – ﹤0.01% 3153
2017
Q4 		$652K Hold
195,411
– – ﹤0.01% 3260
2017
Q3 		$414K Hold
195,411
– – ﹤0.01% 3428
2017
Q2 		$480K Buy
195,411
+86,400
+79% +$230K ﹤0.01% 3368
2017
Q1 		$250K Buy
109,011
+774
+0.7% +$1.17K ﹤0.01% 3576
2016
Q4 		$106K Buy
108,237
+516
+0.5% +$459 ﹤0.01% 3778
2016
Q3 		$121K Buy
107,721
+129
+0.1% +$229 ﹤0.01% 3761
2016
Q2 		$158K Hold
107,592
– – ﹤0.01% 3664
2016
Q1 		$153 Sell
107,592
-129
-0.1% -$173 ﹤0.01% 3708
2015
Q4 		$176K Buy
107,721
+7,612
+8% +$17.4K ﹤0.01% 3725
2015
Q3 		$234K Buy
100,109
+258
+0.3% +$608 ﹤0.01% 3621
2015
Q2 		$272K Sell
99,851
-14,748
-13% -$44.5K ﹤0.01% 3473
2015
Q1 		$383K Buy
114,599
+4,392
+4% +$15.7K ﹤0.01% 3302
2014
Q4 		$382K Buy
110,207
+162
+0.1% +$716 ﹤0.01% 3303
2014
Q3 		$553K Buy
110,045
+108
+0.1% +$841 ﹤0.01% 3118
2014
Q2 		$1.52M Buy
109,937
+35,865
+48% +$446K ﹤0.01% 2545
2014
Q1 		$1.13M Buy
74,072
+1,203
+2% +$17.1K ﹤0.01% 2709
2013
Q4 		$588K Buy
72,869
+28,484
+64% +$263K ﹤0.01% 3013
2013
Q3 		$443K Buy
44,385
+11,257
+34% +$75.9K ﹤0.01% 3006
2013
Q2 		$141K Buy
+33,128
New +$136K ﹤0.01% 3337

Other funds holding GALT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Geode Capital Management's GALT Position: Q1 2026 in Review

Geode Capital Management increased its Galectin Therapeutics (GALT) stake by 2.5% in Q1 2026, buying an estimated $44.8K and bringing the position to 612,786 shares worth $1.71M. The position accounts for ﹤0.01% of the portfolio, ranked #3185.

Geode Capital Management first reported a position in GALT in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.68M in Q3 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q1 2026.

  • Geode Capital Management held 612,786 shares of Galectin Therapeutics worth $1.71M as of Q1 2026.
  • Geode Capital Management bought 14,712 Galectin Therapeutics shares in Q1 2026, an estimated $44.8K.
  • Galectin Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3185 holding.
  • Geode Capital Management first reported a position in Galectin Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Geode Capital Management's Galectin Therapeutics position peaked at $2.68M in Q3 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.